add directory ♦ medical jobs ♦ physician jobs
Today's News:
Pharma Industry / Biotech Industry News From Medical News Today
Amgen And Wyeth Statement On The FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers
Sat, 06 Sep 2008 08:00:00 -0700
Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), issued a statement in response to the Food and Drug Administration (FDA) safety announcement regarding opportunistic fungal infections in patients treated with Tumor Necrosis Factor (TNF) blockers [marketed as Remicade® (infliximab), Enbrel® (etanercept), Humira® (adalimumab) and Cimzia® (certolizumab pegol)].
USP's 2008 Annual Scientific Meeting To Convene Scientific Experts From Around The World
Sat, 06 Sep 2008 05:00:00 -0700
The U.S. Pharmacopeial (USP) Convention's 2008 Annual Scientific Meeting (ASM) will be held in Kansas City, Mo., September 24 to 26. The meeting is an opportunity to interact with the USP experts responsible for establishing internationally recognized standards for prescription and over-the-counter medicines, food ingredients and dietary supplements. The focus will be on Quality of Manufactured Medicines, Food Ingredients and Dietary Supplements.
An Essential And Comprehensive Report On Biopharmaceuticals In The US And European Markets, By Research And Markets
Sat, 06 Sep 2008 03:00:00 -0700
Research and Markets has announced the addition of the "Biopharmaceuticals in the US and European Markets" report to their offering.
SARcode And Sunesis Announce Start Of Phase 1 Clinical Trial In Ocular Inflammatory Diseases
Sat, 06 Sep 2008 01:00:00 -0700
SARcode Corporation, a private company focused on small molecule LFA-1 inhibitors to treat inflammatory diseases, and Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced SARcode's initiation of a Phase 1 clinical trial of a small molecule LFA-1 product candidate for T-cell mediated ophthalmic diseases.
FDA Approves First Hepatitis B Viral Load Test
Sat, 06 Sep 2008 01:00:00 -0700
The U.S. Food & Drug Administration (FDA) has approved the Roche COBAS(R) TaqMan(R) HBV Test, the first assay for quantitating Hepatitis B Virus DNA approved in the U.S. The test uses Roche's real-time PCR technology to quantify the amount of Hepatitis B virus DNA in a patient's blood. Doctors may use viral load testing results to establish a baseline level of infection and during treatment as an aid in assessing individual responses to therapy.
Celator Pharmaceuticals Receives Orphan Drug Designation For Anticancer Agent CPX-351
Sat, 06 Sep 2008 01:00:00 -0700
Celator Pharmaceuticals announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to CPX-351 (Cytarabine:Daunorubicin) Liposome Injection for the treatment of Acute Myeloid Leukemia (AML). Celator is currently preparing to conduct two randomized Phase 2 studies with CPX-351. The first Phase 2 study, in newly diagnosed, elderly patients with AML, is expected to start enrolling patients before the end of 2008.
Annals of Pharmacotherapy PAP Articles
Bevacizumab Sterility in Multiple Doses from a Single-Use Vial (October)
Ornek, K., Karahan, Z. C., Ergin, A., Tekeli, A., Tekeli, O. Tue, 02 Sep 2008 00:00:00 -0000
BACKGROUND: Recent reports have demonstrated that refrigerated bevacizumab can be stored for up to 3 weeks at 4 °C without loss of efficacy. There have been no previous reports addressing bevacizumab's sterility when stored and used as multiple doses from a single-use vial. OBJECTIVE: To evaluate the sterility of bevacizumab when used as multiple doses from a single-use vial. METHODS: Four groups of vials were used to simulate the storage and use conditions for bevacizumab. Each group contained 11 doses of 0.2 mL of bevacizumab. One sample from each group was cultured once each day at 37 °C for 10 days; one sample from each group was left for 15 days. MacConkey agar, blood agar, thioglycollate broth, and Sabouraud medium were used to assess bacterial and fungal growth. RESULTS: A total of 44 samples of bevacizumab were included in this study. Each sample was placed on 4 growth media for microbial readings. All samples were found to be negative for microbial growth. No significant differences were observed among the groups. Possible limitations of this study included the number of samples for each group and in vitro design of the study, which might have affected the growth of bacterial organisms. CONCLUSIONS: Storage and multiple use of bevacizumab from single-use vials does not seem to result in microbial contamination.
Correction: Aspirin, Clopidogrel, and Warfarin: Is the Combination Appropriate and Effective or Inappropriate and Too Dangerous?(October)
Tue, 02 Sep 2008 00:00:00 -0000
Thiazolidinediones in Type 2 Diabetes: A Cardiology Perspective (October | FREE)
Khanderia, U., Pop-Busui, R., Eagle, K. A Tue, 12 Aug 2008 00:00:00 -0000
OBJECTIVE: To examine the cardiovascular effects of thiazolidinediones (TZDs), discuss concerns regarding this drug class and its relation to heart failure (HF) and myocardial infarction (MI), and address the clinical implications of HF and MI. DATA SOURCES: Literature was accessed through MEDLINE (1979-April 2008) using the search terms type 2 diabetes mellitus, thiazolidinediones, cardiovascular events, heart failure, myocardial infarction, and edema. Reviews, meta-analyses, clinical trials, observational studies (case-control, cohort), and descriptive studies (case reports, case series) were included. STUDY SELECTION AND DATA EXTRACTION: All articles that were written in English and identified from the data sources were reviewed. DATA SYNTHESIS: The American Diabetes Association recommends metformin as first-line therapy for type 2 diabetes, with the subsequent addition of a TZD, sulfonylurea, or insulin if the target is not met. Beyond glucose lowering, TZDs improve various factors associated with cardiovascular risk. Whether the effects translate into beneficial cardiovascular outcomes is controversial. In PROactive (Prospective Pioglitazone Clinical Trial in Macrovascular Events), pioglitazone did not produce a significant reduction in the primary endpoint that included a composite of coronary and vascular deaths, but the secondary composite endpoint of all-cause mortality, MI, or stroke was significantly reduced. Concerns related to HF have led to warnings in the labeling of TZDs. The drugs are contraindicated in patients with New York Heart Association Class III or IV HF. Rosiglitazone, but not pioglitazone, is associated with an increased risk of myocardial ischemic events, although the absolute magnitude is extremely small. CONCLUSIONS: Although the glycemic efficacy of TZDs is comparable to that of metformin, adverse effects and higher costs make TZDs less appealing for initial therapy. Among the TZDs, pioglitazone should be considered based on cardiovascular safety data. In combination with metformin, pioglitazone may be particularly beneficial for patients with diabetes and metabolic syndrome. For patients on rosiglitazone who are achieving glycemic goals and tolerating the therapy without apparent complications, rosiglitazone may be continued.
Managing & Leading: 44 Lessons Learned for Pharmacists (October)
Mazur, J. E Tue, 02 Sep 2008 00:00:00 -0000
The Top 100 Drug Interactions: A Guide to Patient Management, 2008 Edition (October)
Karpinski, J. P Tue, 02 Sep 2008 00:00:00 -0000
Bevacizumab: A Treatment Option for Recurrent Glioblastoma Multiforme (October)
Buie, L. W, Valgus, J. M Tue, 02 Sep 2008 00:00:00 -0000
OBJECTIVE: To review the available literature evaluating the effect of bevacizumab on progression-free survival when used in combination with irinotecan for recurrent glioblastoma multiforme (GBM). DATA SOURCES: Searches of MEDLINE (1966-June 2008), the Cochrane Library, and International Pharmaceutical Abstracts (1970-June 2008) were conducted using the terms bevacizumab, irinotecan, and glioblastoma multiforme. STUDY SELECTION AND DATA EXTRACTION: The search was limited to studies conducted in humans. All articles identified from the data sources were evaluated. All clinical trials evaluating the efficacy and safety of bevacizumab in the treatment of recurrent GBM were included in the review. DATA SYNTHESIS: Hypoxia, mutagenesis, and the secretion of various growth factors can all lead to production of vascular endothelial growth factor (VEGF), a proangiogenic growth factor, and angiogenesis in GBM. Neoplastic progression is dependent on angiogenesis, and anti-VEGF therapy has been successful in multiple disease states. However, there are currently no available anti-VEGF therapies approved for treatment of GBM. Bevacizumab is a humanized monoclonal antibody that binds to and inhibits the activity of VEGF. When compared with data from clinical trials that use single chemotherapeutic agents in recurrent GBM, the addition of bevacizumab to cytotoxic chemotherapy, such as irinotecan, appears to improve progression-free survival in patients progressing on the standard of care, with a 6-month progression-free survival rate of 46%. Bevacizumab is well tolerated by most patients, with modest risk (11% in Phase 2 trials) of venous thromboembolism. CONCLUSIONS: Although the combination of bevacizumab and irinotecan is producing positive results in patients with recurrent GBM, larger, randomized clinical trials need to be performed to determine the magnitude of the benefit from bevacizumab. Bevacizumab administered biweekly at a dose of 10 mg/kg in combination with irinotecan may improve progression-free survival.
Clinical Pharmacology & Therapeutics
In This Issue
In This Issue Clinical Pharmacology & Therapeutics 84, 285 (September 2008). doi:10.1038/clpt.2008.162
Is This the Drug or Dose for You?: Impact and Consideration of Ethnic Factors in Global Drug Development, Regulatory Review, and Clinical Practice
S-M HuangR Temple Is This the Drug or Dose for You?: Impact and Consideration of Ethnic Factors in Global Drug Development, Regulatory Review, and Clinical Practice Clinical Pharmacology & Therapeutics 84, 287 (September 2008). doi:10.1038/clpt.2008.144 Authors: S-M Huang & R Temple
Highlights
Highlights Clinical Pharmacology & Therapeutics 84, 296 (September 2008). doi:10.1038/clpt.2008.163 Author:
ASCPT News
ASCPT News Clinical Pharmacology & Therapeutics 84, 298 (September 2008). doi:10.1038/clpt.2008.164
The Critical Path of Warfarin Dosing: Finding an Optimal Dosing Strategy Using Pharmacogenetics
LJ Lesko The Critical Path of Warfarin Dosing: Finding an Optimal Dosing Strategy Using Pharmacogenetics Clinical Pharmacology & Therapeutics 84, 301 (September 2008). doi:10.1038/clpt.2008.133 Author: LJ Lesko
Warfarin and Pharmacogenomic Testing: The Case for Restraint
DA Garcia Warfarin and Pharmacogenomic Testing: The Case for Restraint Clinical Pharmacology & Therapeutics 84, 303 (September 2008). doi:10.1038/clpt.2008.131 Author: DA Garcia
Subscribe to Pharmacology RSS feed 
Amgen And Wyeth Statement On The FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers
Sat, 06 Sep 2008 08:00:00 -0700
Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), issued a statement in response to the Food and Drug Administration (FDA) safety announcement regarding opportunistic fungal infections in patients treated with Tumor Necrosis Factor (TNF) blockers [marketed as Remicade® (infliximab), Enbrel® (etanercept), Humira® (adalimumab) and Cimzia® (certolizumab pegol)].
USP's 2008 Annual Scientific Meeting To Convene Scientific Experts From Around The World
Sat, 06 Sep 2008 05:00:00 -0700
The U.S. Pharmacopeial (USP) Convention's 2008 Annual Scientific Meeting (ASM) will be held in Kansas City, Mo., September 24 to 26. The meeting is an opportunity to interact with the USP experts responsible for establishing internationally recognized standards for prescription and over-the-counter medicines, food ingredients and dietary supplements. The focus will be on Quality of Manufactured Medicines, Food Ingredients and Dietary Supplements.
An Essential And Comprehensive Report On Biopharmaceuticals In The US And European Markets, By Research And Markets
Sat, 06 Sep 2008 03:00:00 -0700
Research and Markets has announced the addition of the "Biopharmaceuticals in the US and European Markets" report to their offering.
SARcode And Sunesis Announce Start Of Phase 1 Clinical Trial In Ocular Inflammatory Diseases
Sat, 06 Sep 2008 01:00:00 -0700
SARcode Corporation, a private company focused on small molecule LFA-1 inhibitors to treat inflammatory diseases, and Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced SARcode's initiation of a Phase 1 clinical trial of a small molecule LFA-1 product candidate for T-cell mediated ophthalmic diseases.
FDA Approves First Hepatitis B Viral Load Test
Sat, 06 Sep 2008 01:00:00 -0700
The U.S. Food & Drug Administration (FDA) has approved the Roche COBAS(R) TaqMan(R) HBV Test, the first assay for quantitating Hepatitis B Virus DNA approved in the U.S. The test uses Roche's real-time PCR technology to quantify the amount of Hepatitis B virus DNA in a patient's blood. Doctors may use viral load testing results to establish a baseline level of infection and during treatment as an aid in assessing individual responses to therapy.
Celator Pharmaceuticals Receives Orphan Drug Designation For Anticancer Agent CPX-351
Sat, 06 Sep 2008 01:00:00 -0700
Celator Pharmaceuticals announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to CPX-351 (Cytarabine:Daunorubicin) Liposome Injection for the treatment of Acute Myeloid Leukemia (AML). Celator is currently preparing to conduct two randomized Phase 2 studies with CPX-351. The first Phase 2 study, in newly diagnosed, elderly patients with AML, is expected to start enrolling patients before the end of 2008.
Annals of Pharmacotherapy PAP Articles
Bevacizumab Sterility in Multiple Doses from a Single-Use Vial (October)
Ornek, K., Karahan, Z. C., Ergin, A., Tekeli, A., Tekeli, O. Tue, 02 Sep 2008 00:00:00 -0000
BACKGROUND: Recent reports have demonstrated that refrigerated bevacizumab can be stored for up to 3 weeks at 4 °C without loss of efficacy. There have been no previous reports addressing bevacizumab's sterility when stored and used as multiple doses from a single-use vial. OBJECTIVE: To evaluate the sterility of bevacizumab when used as multiple doses from a single-use vial. METHODS: Four groups of vials were used to simulate the storage and use conditions for bevacizumab. Each group contained 11 doses of 0.2 mL of bevacizumab. One sample from each group was cultured once each day at 37 °C for 10 days; one sample from each group was left for 15 days. MacConkey agar, blood agar, thioglycollate broth, and Sabouraud medium were used to assess bacterial and fungal growth. RESULTS: A total of 44 samples of bevacizumab were included in this study. Each sample was placed on 4 growth media for microbial readings. All samples were found to be negative for microbial growth. No significant differences were observed among the groups. Possible limitations of this study included the number of samples for each group and in vitro design of the study, which might have affected the growth of bacterial organisms. CONCLUSIONS: Storage and multiple use of bevacizumab from single-use vials does not seem to result in microbial contamination.
Correction: Aspirin, Clopidogrel, and Warfarin: Is the Combination Appropriate and Effective or Inappropriate and Too Dangerous?(October)
Tue, 02 Sep 2008 00:00:00 -0000
Thiazolidinediones in Type 2 Diabetes: A Cardiology Perspective (October | FREE)
Khanderia, U., Pop-Busui, R., Eagle, K. A Tue, 12 Aug 2008 00:00:00 -0000
OBJECTIVE: To examine the cardiovascular effects of thiazolidinediones (TZDs), discuss concerns regarding this drug class and its relation to heart failure (HF) and myocardial infarction (MI), and address the clinical implications of HF and MI. DATA SOURCES: Literature was accessed through MEDLINE (1979-April 2008) using the search terms type 2 diabetes mellitus, thiazolidinediones, cardiovascular events, heart failure, myocardial infarction, and edema. Reviews, meta-analyses, clinical trials, observational studies (case-control, cohort), and descriptive studies (case reports, case series) were included. STUDY SELECTION AND DATA EXTRACTION: All articles that were written in English and identified from the data sources were reviewed. DATA SYNTHESIS: The American Diabetes Association recommends metformin as first-line therapy for type 2 diabetes, with the subsequent addition of a TZD, sulfonylurea, or insulin if the target is not met. Beyond glucose lowering, TZDs improve various factors associated with cardiovascular risk. Whether the effects translate into beneficial cardiovascular outcomes is controversial. In PROactive (Prospective Pioglitazone Clinical Trial in Macrovascular Events), pioglitazone did not produce a significant reduction in the primary endpoint that included a composite of coronary and vascular deaths, but the secondary composite endpoint of all-cause mortality, MI, or stroke was significantly reduced. Concerns related to HF have led to warnings in the labeling of TZDs. The drugs are contraindicated in patients with New York Heart Association Class III or IV HF. Rosiglitazone, but not pioglitazone, is associated with an increased risk of myocardial ischemic events, although the absolute magnitude is extremely small. CONCLUSIONS: Although the glycemic efficacy of TZDs is comparable to that of metformin, adverse effects and higher costs make TZDs less appealing for initial therapy. Among the TZDs, pioglitazone should be considered based on cardiovascular safety data. In combination with metformin, pioglitazone may be particularly beneficial for patients with diabetes and metabolic syndrome. For patients on rosiglitazone who are achieving glycemic goals and tolerating the therapy without apparent complications, rosiglitazone may be continued.
Managing & Leading: 44 Lessons Learned for Pharmacists (October)
Mazur, J. E Tue, 02 Sep 2008 00:00:00 -0000
The Top 100 Drug Interactions: A Guide to Patient Management, 2008 Edition (October)
Karpinski, J. P Tue, 02 Sep 2008 00:00:00 -0000
Bevacizumab: A Treatment Option for Recurrent Glioblastoma Multiforme (October)
Buie, L. W, Valgus, J. M Tue, 02 Sep 2008 00:00:00 -0000
OBJECTIVE: To review the available literature evaluating the effect of bevacizumab on progression-free survival when used in combination with irinotecan for recurrent glioblastoma multiforme (GBM). DATA SOURCES: Searches of MEDLINE (1966-June 2008), the Cochrane Library, and International Pharmaceutical Abstracts (1970-June 2008) were conducted using the terms bevacizumab, irinotecan, and glioblastoma multiforme. STUDY SELECTION AND DATA EXTRACTION: The search was limited to studies conducted in humans. All articles identified from the data sources were evaluated. All clinical trials evaluating the efficacy and safety of bevacizumab in the treatment of recurrent GBM were included in the review. DATA SYNTHESIS: Hypoxia, mutagenesis, and the secretion of various growth factors can all lead to production of vascular endothelial growth factor (VEGF), a proangiogenic growth factor, and angiogenesis in GBM. Neoplastic progression is dependent on angiogenesis, and anti-VEGF therapy has been successful in multiple disease states. However, there are currently no available anti-VEGF therapies approved for treatment of GBM. Bevacizumab is a humanized monoclonal antibody that binds to and inhibits the activity of VEGF. When compared with data from clinical trials that use single chemotherapeutic agents in recurrent GBM, the addition of bevacizumab to cytotoxic chemotherapy, such as irinotecan, appears to improve progression-free survival in patients progressing on the standard of care, with a 6-month progression-free survival rate of 46%. Bevacizumab is well tolerated by most patients, with modest risk (11% in Phase 2 trials) of venous thromboembolism. CONCLUSIONS: Although the combination of bevacizumab and irinotecan is producing positive results in patients with recurrent GBM, larger, randomized clinical trials need to be performed to determine the magnitude of the benefit from bevacizumab. Bevacizumab administered biweekly at a dose of 10 mg/kg in combination with irinotecan may improve progression-free survival.
Clinical Pharmacology & Therapeutics
In This Issue
In This Issue Clinical Pharmacology & Therapeutics 84, 285 (September 2008). doi:10.1038/clpt.2008.162
Is This the Drug or Dose for You?: Impact and Consideration of Ethnic Factors in Global Drug Development, Regulatory Review, and Clinical Practice
S-M HuangR Temple Is This the Drug or Dose for You?: Impact and Consideration of Ethnic Factors in Global Drug Development, Regulatory Review, and Clinical Practice Clinical Pharmacology & Therapeutics 84, 287 (September 2008). doi:10.1038/clpt.2008.144 Authors: S-M Huang & R Temple
Highlights
Highlights Clinical Pharmacology & Therapeutics 84, 296 (September 2008). doi:10.1038/clpt.2008.163 Author:
ASCPT News
ASCPT News Clinical Pharmacology & Therapeutics 84, 298 (September 2008). doi:10.1038/clpt.2008.164
The Critical Path of Warfarin Dosing: Finding an Optimal Dosing Strategy Using Pharmacogenetics
LJ Lesko The Critical Path of Warfarin Dosing: Finding an Optimal Dosing Strategy Using Pharmacogenetics Clinical Pharmacology & Therapeutics 84, 301 (September 2008). doi:10.1038/clpt.2008.133 Author: LJ Lesko
Warfarin and Pharmacogenomic Testing: The Case for Restraint
DA Garcia Warfarin and Pharmacogenomic Testing: The Case for Restraint Clinical Pharmacology & Therapeutics 84, 303 (September 2008). doi:10.1038/clpt.2008.131 Author: DA Garcia
Sites:
Annual PET Pharmacokinetic Course: Course on application of PET to pharmacokinetics, open to professionals in a wide variety of fields. Held at different locations around the world, next is June 2003 in Montreal, Canada.ATLANTA PHARMA: Atlanta Pharma, Inc. has evolved into a specialty pharmaceutical company, focused on developing, manufacturing and marketing brand and generic pharmaceutical products utilizing various drug delivery technologies.
Cytochrome P450: Identification of a novel transcriptional silencer in the protein-coding region of the human cytochrome P450 2C9 gene.
Department of Pharmacology and Toxicology, School of Medicine, University of Puerto Rico: Department of Pharmacology and Toxicology; University of Puerto Rico; Information about the department and the graduate program in Pharmacology and Toxicology., Department of Pharmacology and Toxicology; University of Puerto Rico; Information about the department and the graduate program in Pharm...
Department of Preclinical and Clinical Pharmacology, University of Florence, Italy: Information on research activities in Pharmacology.
Dissolution Solutions Network: Dissolution Solutions Network: Pharmaceutical scientists providing real answers for one another. The latest news, forum, blog and more...
DrugInfo. Searching the Web for Drug Information: A personal Website based on 30-years experience in pharmacology. Provides help to Web browsers in locating the most relevant drug information on the Web.
Elliot Brown Consulting: MedDRA training, products and pharmacovigilance by Dr Elliot Brown Consultancy.Pharmaceutical regulatory affairs, Adverse experiences, adverse events, drug safety surveillance, post marketing surveillance, EMEA, SPMP, MCA ,
FDA Drug Approvals List: Updated weekly as a service by CDER's Division of Data Management and Services.
Institute of Pharmacology University of Bern Switzerland: Information about the institute, its history, research areas and staff.
Institute of Pharmacology, Polish Academy of Sciences: Information about the Institute and its neuropharmacological research, including psychotropic drugs.
Laboratory of Pulmonary Pharmacology: research in human vascular pharmacology, reactivity of bronchial and vascular tissues, role of the eicosanoids and the cholinergic system
New York University Department of Pharmacology: Teaching of medical and graduate students, with research programs in normal growth and differentiation, development and pathology of the nervous system, and mechanisms of normal and abnormal functions of several key hormones.
Novartis Pharma: Here you'll find expert information about diseases, treatments and the full Novartis US product line, and an inside look at where we're headed.
Optimizing a Unimodal Response Function for Binary Variables: Adaptive designs for optimizing a unimodal response function for binary variables.
Ottosen Site for Drug Safety and Pharmacovigilance: Information about drug safety and clinical studies. Includes discussion forum, news and practical information about issues like safety reporting, licensing, contracts, PSUR, E2B, electronic submission.
Pharmacology and Legal Drugs - About.com: Search the power of About's network of topics
Pharmacology-Info.com: Information about pharmacology, toxicology, getting a new drug to market, and FDA approval.
SMR's Case Histories of Drug Discovery: Drug symposium organized by Society for Medicines Research, drug discovery of infliximab, zanamivir, olanzapine, alosetron, leflunomide and celecoxib.
Social Audit - the Antidepressant Web: social audit
The Lycaeum: An Entheogenic Database: The Lycaeum features an entheogen information database, drug experience archive with over 700 reports, search engine which spiders several major drug information sites, psychedelic graphics, transcribed books, community, software, audio, hosted sites, and much more.
The Ones That Stain Blue: Dr. Albert Hofmann
The Virtual Clinical Pharmacologist: Development of inpatient and outpatient anticoagulation and clinical pharmacology services. In conjunction with this we offer several multi-media CD rom products to assist the user in the development of these services. On line lectures are available .
TICTAC: The CD-ROM for drug identification of tablets & capsules
Toxicology-Info.com: Information on toxicology, drug interactions, toxicity and adverse reactions. Part of the ALtruis Biomedical Network.
University of Colorado Health Sciences Center - Department of Pharmacology: Department of Pharmacology and Graduate Program in Pharmacology at the University of Colorado Health Sciences Center at Denver and information about our pharmacology graduate program, curriculum, and research activities in the Pharmacology department. Research interests include: bioinformatics, m...
This directory is based on the Open Directory and may have been modified